東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Pharmacogenetic studies of membrane ...

Badagnani, Ilaria.

Linked to FindBook

Google Book

Amazon

博客來

Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy./
Author:	Badagnani, Ilaria.
Description:	256 p.
Notes:	Source: Dissertation Abstracts International, Volume: 68-01, Section: B, page: 0227.
Contained By:	Dissertation Abstracts International68-01B.
Subject:	Health Sciences, Pharmacology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3247846

Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy.
Badagnani, Ilaria.

Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy. - 256 p.

Source: Dissertation Abstracts International, Volume: 68-01, Section: B, page: 0227.

Thesis (Ph.D.)--University of California, San Francisco, 2006.

Membrane transporters are important determinants of drug disposition and response. The goals of this dissertation are to examine the interaction of membrane transporters with anti-cancer drugs, in particular cladribine, fludarabine, and methotrexate, and to analyze their genetic and functional diversity. We showed that the human concentrative nucleoside transporter CNT3 (SLC28A3), which transports nucleoside analogs, is under negative selective pressure. The rare variant, protein reference sequence (p.) Gly367Arg, exhibited reduced transport of nucleosides, whereas common non-synonymous variants of CNT3 exhibited no change in their transport of nucleosides, suggesting that common coding region variants of CNT3 do not contribute to common variation in the efficacy of cladribine and fludarabine. Methotrexate exhibits variable pharmacokinetics and renal toxicity. We showed that the human organic anion transporting polypeptide, OATP1A2 (SLCO1A2 ) transports methotrexate in a pH-dependent manner. Since the human organic anion transporter OAT3 (SLC22A8) and OATP1A2 are expressed in the renal tubule, they may play a role in the elimination and nephrotoxicity of methotrexate. We identified four protein-altering variants in OATP1A2 and six in OAT3 that had altered transport of methotrexate, suggesting that these variants may contribute to variation in the renal disposition and toxicity of methotrexate. We characterized the mechanism of transport and identified critical amino acid residues in OATP1A2 that are responsible for methotrexate uptake. The enhanced transport at acidic pH resulted from increased substrate affinity and did not depend on the proton gradient. Conserved cationic residues in OATP1A2 were important in methotrexate recognition and uptake. Lastly, we initiated collaborative studies to examine the characteristics of methotrexate elimination in patients with acute lymphoblastic leukemia (ALL). Methotrexate pharmacokinetics were non-linear and highly variable. Increased exposure to methotrexate was associated with delayed elimination. In future studies, we will genotype ALL patients for 11 variants and 16 haplotypes in 6 kidney transporters to analyze the contribution of kidney transporters to variation in MTX pharmacokinetics and renal toxicity. These studies have enhanced our understanding of how membrane transporters interact with anti-cancer drugs and, thereby, control their systemic and tissue levels. Genetic variation in these transporters may contribute to variation in the efficacy and toxicity of anti-cancer drugs.Subjects--Topical Terms:

1017717
Health Sciences, Pharmacology.

Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy.
LDR:03450nmm 2200253 4500 001 1834476
005 20071119145700.5
008 130610s2006 eng d
035 $a (UMI)AAI3247846
035 $a AAI3247846
040 $a UMI $c UMI
100 1 $a Badagnani, Ilaria. $3 1923127
245 1 0 $a Pharmacogenetic studies of membrane transporters relevant to anti-cancer drug therapy.
300 $a 256 p.
500 $a Source: Dissertation Abstracts International, Volume: 68-01, Section: B, page: 0227.
500 $a Adviser: Kathleen M. Giacomini.
502 $a Thesis (Ph.D.)--University of California, San Francisco, 2006.
520 $a Membrane transporters are important determinants of drug disposition and response. The goals of this dissertation are to examine the interaction of membrane transporters with anti-cancer drugs, in particular cladribine, fludarabine, and methotrexate, and to analyze their genetic and functional diversity. We showed that the human concentrative nucleoside transporter CNT3 (SLC28A3), which transports nucleoside analogs, is under negative selective pressure. The rare variant, protein reference sequence (p.) Gly367Arg, exhibited reduced transport of nucleosides, whereas common non-synonymous variants of CNT3 exhibited no change in their transport of nucleosides, suggesting that common coding region variants of CNT3 do not contribute to common variation in the efficacy of cladribine and fludarabine. Methotrexate exhibits variable pharmacokinetics and renal toxicity. We showed that the human organic anion transporting polypeptide, OATP1A2 (SLCO1A2 ) transports methotrexate in a pH-dependent manner. Since the human organic anion transporter OAT3 (SLC22A8) and OATP1A2 are expressed in the renal tubule, they may play a role in the elimination and nephrotoxicity of methotrexate. We identified four protein-altering variants in OATP1A2 and six in OAT3 that had altered transport of methotrexate, suggesting that these variants may contribute to variation in the renal disposition and toxicity of methotrexate. We characterized the mechanism of transport and identified critical amino acid residues in OATP1A2 that are responsible for methotrexate uptake. The enhanced transport at acidic pH resulted from increased substrate affinity and did not depend on the proton gradient. Conserved cationic residues in OATP1A2 were important in methotrexate recognition and uptake. Lastly, we initiated collaborative studies to examine the characteristics of methotrexate elimination in patients with acute lymphoblastic leukemia (ALL). Methotrexate pharmacokinetics were non-linear and highly variable. Increased exposure to methotrexate was associated with delayed elimination. In future studies, we will genotype ALL patients for 11 variants and 16 haplotypes in 6 kidney transporters to analyze the contribution of kidney transporters to variation in MTX pharmacokinetics and renal toxicity. These studies have enhanced our understanding of how membrane transporters interact with anti-cancer drugs and, thereby, control their systemic and tissue levels. Genetic variation in these transporters may contribute to variation in the efficacy and toxicity of anti-cancer drugs.
590 $a School code: 0034.
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0419
710 2 0 $a University of California, San Francisco. $3 1025118
773 0 $t Dissertation Abstracts International $g 68-01B.
790 1 0 $a Giacomini, Kathleen M., $e advisor
790 $a 0034
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3247846